PMID- 27910042
OWN - NLM
STAT- MEDLINE
DCOM- 20180115
LR  - 20181113
IS  - 1940-6029 (Electronic)
IS  - 1064-3745 (Print)
IS  - 1064-3745 (Linking)
VI  - 1521
DP  - 2017
TI  - Direct Cardiac Reprogramming as a Novel Therapeutic Strategy for Treatment of 
      Myocardial Infarction.
PG  - 69-88
AB  - Direct reprogramming of fibroblasts into induced cardiomyocytes (iCMs) holds 
      great promise as a novel therapy for the treatment of heart failure, a common and 
      morbid disease that is usually caused by irreversible loss of functional 
      cardiomyocytes (CMs). Recently, we and others showed that in a murine model of 
      acute myocardial infarction, delivery of three transcription factors, Gata4, 
      Mef2c, and Tbx5 converted endogenous cardiac fibroblasts into functional iCMs. 
      These iCMs integrated electrically and mechanically with surrounding myocardium, 
      resulting in a reduction in scar size and an improvement in heart function. Our 
      findings suggest that iCM reprogramming may be a means of regenerating functional 
      CMs in vivo for patients with heart disease. However, because relatively little 
      is known about the factors that regulate iCM reprogramming, the applicability of 
      iCM reprogramming is currently limited to the experimental settings in which it 
      has been attempted. Specific hurdles include the relatively low conversion rate 
      of iCMs and the need for reprogramming to occur in the context of acute injury. 
      Therefore, before this treatment can become a viable therapy for human heart 
      disease, the optimal condition for efficient iCM generation must be determined. 
      Here, we provide a detailed protocol for both in vitro and in vivo iCM generation 
      that has been optimized so far in our lab. We hope that this protocol will lay a 
      foundation for future further improvement of iCM generation and provide a 
      platform for mechanistic studies.
FAU - Ma, Hong
AU  - Ma H
AD  - Department of Pathology and Laboratory Medicine, McAllister Heart Institute, 
      University of North Carolina, 3340B Medical Bioresearch Building, 111 Mason Farm 
      Rd, Chapel Hill, NC, 27599, USA.
FAU - Wang, Li
AU  - Wang L
AD  - Department of Pathology and Laboratory Medicine, McAllister Heart Institute, 
      University of North Carolina, 3340B Medical Bioresearch Building, 111 Mason Farm 
      Rd, Chapel Hill, NC, 27599, USA.
FAU - Liu, Jiandong
AU  - Liu J
AD  - Department of Pathology and Laboratory Medicine, McAllister Heart Institute, 
      University of North Carolina, 3340B Medical Bioresearch Building, 111 Mason Farm 
      Rd, Chapel Hill, NC, 27599, USA.
FAU - Qian, Li
AU  - Qian L
AD  - Department of Pathology and Laboratory Medicine, McAllister Heart Institute, 
      University of North Carolina, 3340B Medical Bioresearch Building, 111 Mason Farm 
      Rd, Chapel Hill, NC, 27599, USA. li_qian@med.unc.edu.
LA  - eng
GR  - R00 HL109079/HL/NHLBI NIH HHS/United States
GR  - R01 HL128331/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Methods Mol Biol
JT  - Methods in molecular biology (Clifton, N.J.)
JID - 9214969
SB  - IM
MH  - Animals
MH  - *Cellular Reprogramming
MH  - Disease Models, Animal
MH  - Gene Expression Regulation
MH  - Mice
MH  - Myocardial Infarction/*therapy
MH  - Myocytes, Cardiac/*cytology
MH  - NIH 3T3 Cells
MH  - Retroviridae/metabolism
PMC - PMC5376348
MID - NIHMS853693
OTO - NOTNLM
OT  - Cell reprogramming
OT  - Fibroblast
OT  - Induced cardiomyocyte
OT  - Myocardial infarction
OT  - Regeneration
EDAT- 2016/12/03 06:00
MHDA- 2018/01/16 06:00
PMCR- 2017/04/01
CRDT- 2016/12/03 06:00
PHST- 2016/12/03 06:00 [entrez]
PHST- 2016/12/03 06:00 [pubmed]
PHST- 2018/01/16 06:00 [medline]
PHST- 2017/04/01 00:00 [pmc-release]
AID - 10.1007/978-1-4939-6588-5_5 [doi]
PST - ppublish
SO  - Methods Mol Biol. 2017;1521:69-88. doi: 10.1007/978-1-4939-6588-5_5.